Mucopolysaccharidosis type I (MPS-I), a lysosomal storage disorder caused by a deficiency of alpha-L-iduronidase enzyme, results in the progressive accumulation of glycosaminoglycans and consequent multiorgan dysfunction. Despite the effectiveness of hematopoietic stem cell transplantation (HSCT) and enzyme replacement therapy (ERT) in correcting clinical manifestations related to visceral organs, complete improvement of musculoskeletal and neurocognitive defects remains an unmet challenge and provides an impact on patients' quality of life. We tested the therapeutic efficacy of combining HSCT and ERT in the neonatal period. Using a mouse model of MPS-I, we demonstrated that the combination therapy improved clinical manifestations in organs usually refractory to current treatment. Moreover, combination with HSCT prevented the production of anti-IDUA antibodies that negatively impact ERT efficacy. The added benefits of combining both treatments also resulted in a reduction of skeletal anomalies and a trend towards decreased neuroinflammation and metabolic abnormalities. As currently there are limited therapeutic options for MPS-I patients, our findings suggest that the combination of HSCT and ERT during the neonatal period may provide a further step forward in the treatment of this rare disease.

Santi, L., De Ponti, G., Dina, G., Pievani, A., Corsi, A., Riminucci, M., et al. (2020). Neonatal combination therapy improves some of the clinical manifestations in the Mucopolysaccharidosis type I murine model. MOLECULAR GENETICS AND METABOLISM, 130(3), 197-208-208 [10.1016/j.ymgme.2020.05.001].

Neonatal combination therapy improves some of the clinical manifestations in the Mucopolysaccharidosis type I murine model

Santi L.;De Ponti G.;Pievani A.;Antolini L.;Biondi A.;Serafini M.
2020

Abstract

Mucopolysaccharidosis type I (MPS-I), a lysosomal storage disorder caused by a deficiency of alpha-L-iduronidase enzyme, results in the progressive accumulation of glycosaminoglycans and consequent multiorgan dysfunction. Despite the effectiveness of hematopoietic stem cell transplantation (HSCT) and enzyme replacement therapy (ERT) in correcting clinical manifestations related to visceral organs, complete improvement of musculoskeletal and neurocognitive defects remains an unmet challenge and provides an impact on patients' quality of life. We tested the therapeutic efficacy of combining HSCT and ERT in the neonatal period. Using a mouse model of MPS-I, we demonstrated that the combination therapy improved clinical manifestations in organs usually refractory to current treatment. Moreover, combination with HSCT prevented the production of anti-IDUA antibodies that negatively impact ERT efficacy. The added benefits of combining both treatments also resulted in a reduction of skeletal anomalies and a trend towards decreased neuroinflammation and metabolic abnormalities. As currently there are limited therapeutic options for MPS-I patients, our findings suggest that the combination of HSCT and ERT during the neonatal period may provide a further step forward in the treatment of this rare disease.
Si
Articolo in rivista - Articolo scientifico
Scientifica
Combination approach; Early treatment; ERT; HSCT; Mucopolysaccharidosis type I;
English
197-208
208
Santi, L., De Ponti, G., Dina, G., Pievani, A., Corsi, A., Riminucci, M., et al. (2020). Neonatal combination therapy improves some of the clinical manifestations in the Mucopolysaccharidosis type I murine model. MOLECULAR GENETICS AND METABOLISM, 130(3), 197-208-208 [10.1016/j.ymgme.2020.05.001].
Santi, L; De Ponti, G; Dina, G; Pievani, A; Corsi, A; Riminucci, M; Khan, S; Sawamoto, K; Antolini, L; Gregori, S; Annoni, A; Biondi, A; Quattrini, A; Tomatsu, S; Serafini, M
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/10281/277423
Citazioni
  • Scopus 6
  • ???jsp.display-item.citation.isi??? 6
Social impact